Literature DB >> 23804629

Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C.

Vincent Soriano1, Eugenia Vispo, Carmen de Mendoza, Pablo Labarga, Zulema Plaza, Jose V Fernandez-Montero, Eva Poveda, Ana Treviño, Pablo Barreiro.   

Abstract

Serum HCV RNA rebound beyond 24 weeks after completing hepatitis C therapy has been rarely reported. From 744 patients treated for chronic hepatitis C at our institution, 4 became HCV-RNA-positive again between weeks 36 and 48 post-treatment. Epidemiological and phylogenetic analyses supported very late HCV relapse instead of re-infection in two of them. This observation may have important implications in the pathogenesis and therapeutics of HCV infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23804629     DOI: 10.3851/IMP2659

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  5 in total

Review 1.  Modelling hepatitis C therapy--predicting effects of treatment.

Authors:  Alan S Perelson; Jeremie Guedj
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-06-30       Impact factor: 46.802

2.  Reply: To PMID 24797101.

Authors:  Tamer Abdelrahman; Joseph Hughes; Janice Main; John McLauchlan; Mark Thursz; Emma Thomson
Journal:  Hepatology       Date:  2015-04       Impact factor: 17.425

3.  Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment.

Authors:  Tamer Abdelrahman; Joseph Hughes; Janice Main; John McLauchlan; Mark Thursz; Emma Thomson
Journal:  Hepatology       Date:  2014-07-30       Impact factor: 17.425

4.  Exceptional Heterogeneity in Viral Evolutionary Dynamics Characterises Chronic Hepatitis C Virus Infection.

Authors:  Jayna Raghwani; Rebecca Rose; Isabelle Sheridan; Philippe Lemey; Marc A Suchard; Teresa Santantonio; Patrizia Farci; Paul Klenerman; Oliver G Pybus
Journal:  PLoS Pathog       Date:  2016-09-15       Impact factor: 6.823

5.  Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis.

Authors:  Haruki Uojima; Shuko Murakami; Seigo Nakatani; Hisashi Hidaka; Atsuko Takeuchi; Yoshiaki Tanaka; Tomoyoshi Inoue; Keiko Yamane; Kousuke Kubota; Takahide Nakazawa; Akitaka Shibuya; Yasuhito Tanaka; Wasaburo Koizumi
Journal:  Intern Med       Date:  2017-12-08       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.